

BACIL PHARMA LIMITED

Regd. Off.: 71, LAXMIBUILDING, 4TH FLOOR, SIR P. M. ROAD, FORT, MUMBAI 400 001.
Email ID: bacilpha@yahoo.com CIN: L24200MH1987PLC043427 Tel.: 22618452/22661541, Tel/Fax: 22618327

Date: 27th September, 2024

To,
The Manager
Listing
Department
BSE Limited
Phiroze Jeejeebhoy
Towers, Dalal Street,
Fort
Mumbai-400001

Scrip Code: **524516**
Scrip Id: **BACPHAR**

Sub.: Outcome of Board Meeting Held on September 27, 2024.

Dear Sir,

Pursuant to provisions of Regulation 30 and Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its Meeting held today i.e. September 24, 2024 has approved the Audited Financial Results March 31, 2024 and approved the following key matters:

1. Increase in Authorized Share Capital

The Board discussed and approved a proposal to increase the authorized share capital of the Company to ₹15,00,00,000/-, subject to shareholder approval at the ensuing General Meeting.

(Note: If a further increase in share capital is required, an additional Board meeting will be convened for approval.)

2. Alteration of Capital Clause and Object Clause of the Memorandum of Association (MoA)

The Board approved the proposal to alter the Capital Clause and Object Clause of the MoA to accommodate the increase in authorized capital and other relevant adjustments, subject to shareholder approval at the ensuing General Meeting.

3. Increase in Loan, Investment, and Guarantee Limits under Section 186 of the Companies Act, 2013

The Board approved increasing the limit for granting loans, making investments, and providing guarantees by the Company to ₹100 crore under Section 186 of the Companies Act, 2013.

BACIL PHARMA LIMITED

Regd. Off.: 71, LAXMIBUILDING, 4TH FLOOR, SIR P. M. ROAD, FORT, MUMBAI 400 001.
Email ID: bacilpha@yahoo.com CIN: L24200MH1987PLC043427 Tel.: 22618452/22661541, Tel/Fax: 22618327

4. Increase in Borrowing Limits under Section 180(1)(c) of the Companies Act, 2013

The Board approved an increase in the Company's borrowing limit to ₹100 crore under Section 180(1)(c) of the Companies Act, 2013.

5. Discussion on Investment Proposal through Acquisition of Equity Shares

The Board discussed an initial investment proposal involving the acquisition of paid-up equity share capital of another company from its existing shareholders. The Board decided to defer the final decision on the price and the number of shares to be acquired pending valuations and due diligence of the entity.

6. Fundraising through Issue of Equity Shares

The Board approved the proposal to raise funds by issuing equity shares through permissible modes, such as Preferential Issue, Rights Issue, CCPS, or CCD.

7. Appointment of Intermediaries (Valuers/Consultants)

The Board approved the appointment of the necessary intermediaries, including valuers and consultants, to facilitate the investment proposal, as deemed in the best interest of the Company.

8. Change of Registered Office

The Board approved the proposal to change the registered office of the Company within the same city limits, from:

71, Laxmi Building, Sir P.M. Road, Fort, Mumbai, Maharashtra, 400001

to:

G2 & G3 Samarpan Complex, Next to Mirador Hotel, Chakala, Andheri East, Mumbai - 400099.

You are requested to take this on your record and acknowledge receipt.

The Board Meeting commenced at 4:00 p.m. and concluded at 5.40 p.m.

Thanking You,

For Bacil Pharma Limited

Mehul Shah
Director
DIN: 10753865